Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis by Manasa K. Nayak, Nirav Dhanesha,

Slides:



Advertisements
Similar presentations
Red blood cells mediate the onset of thrombosis in the ferric chloride murine model by Justin D. Barr, Anil K. Chauhan, Gilbert V. Schaeffer, Jessica K.
Advertisements

Chrysin restores PDGF-induced inhibition on protein tyrosine phosphatase and reduces PDGF signaling in cultured VSMCs  Huey-Ming Lo, Min-Wen Wu, Shiow-Lin.
Thymidine Phosphorylase Participates in Platelet Signaling and Promotes ThrombosisNovelty and Significance by Wei Li, Alba Gigante, Maria-Jesus Perez-Perez,
The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation by Fumiaki Banno, Anil K. Chauhan, Koichi Kokame,
Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice by Sravya Kattula, James R. Byrnes,
by Wei Zhang, and Robert W. Colman
Reduced thrombus stability in mice lacking the α2A-adrenergic receptor
Activation of αIIbβ3 is a sufficient but also an imperative prerequisite for activation of α2β1 on platelets by Gerlinde R. Van de Walle, Anne Schoolmeester,
by Matt W. Goschnick, Lai-Man Lau, Janet L. Wee, Yong S. Liu, P
Occlusive thrombi arise in mammals but not birds in response to arterial injury: evolutionary insight into human cardiovascular disease by Alec A. Schmaier,
Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation by Hua-Chen Chan, Liang-Yin.
Defective release of α granule and lysosome contents from platelets in mouse Hermansky-Pudlak syndrome models by Ronghua Meng, Jie Wu, Dawn C. Harper,
Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury by Shahrouz Ghafoory, Rohan Varshney, Tyler Robison, Karim Kouzbari,
PRT , a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model by Michael P. Reilly, Uma Sinha,
Vessel wall BAMBI contributes to hemostasis and thrombus stability
by Kesheng Dai, Richard Bodnar, Michael C. Berndt, and Xiaoping Du
by Hong Yin, Aleksandra Stojanovic, Nissim Hay, and Xiaoping Du
Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin αIIbβ3 by Cindy L. Yap, Karen.
by Simon Stritt, Inga Birkholz, Sarah Beck, Simona Sorrentino, K
Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor–independent fibrin generation by Ton Lisman, Jelle Adelmeijer,
by Zhengyan Wang, Tina M. Leisner, and Leslie V. Parise
by Jun Chung, Xue-Qing Wang, Frederik P. Lindberg, and William A
Alterations in platelet secretion differentially affect thrombosis and hemostasis by Smita Joshi, Meenakshi Banerjee, Jinchao Zhang, Akhil Kesaraju, Irina.
Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets by Brian Boylan, Cunji Gao, Vipul.
A role for the thiol isomerase protein ERP5 in platelet function
Rap1-GTP–interacting adaptor molecule (RIAM) is dispensable for platelet integrin activation and function in mice by Simon Stritt, Karen Wolf, Viola Lorenz,
Two-wavelength near-infrared fluorescence for the quantitation of drug antiplatelet effects in large animal model systems  Yoshitomo Ashitate, MD, Soon.
Β1 integrin−mediated signals are required for platelet granule secretion and hemostasis in mouse by Tobias Petzold, Raphael Ruppert, Dharmendra Pandey,
Impaired activation of platelets lacking protein kinase C-θ isoform
Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury by Ye Tian, Breia Salsbery, Min Wang, Hengjie Yuan,
Coordination of platelet agonist signaling during the hemostatic response in vivo by Jian Shen, Sara Sampietro, Jie Wu, Juan Tang, Shuchi Gupta, Chelsea.
Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation by Eric Boilard, Guillaume Paré, Matthieu Rousseau, Nathalie.
Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase–signaling pathways by Katie.
C1qTNF–related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen by Gerald.
Cobalt hematoporphyrin inhibits CLEC-2–podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice by Nagaharu Tsukiji, Makoto Osada,
Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac by Alice Y. Pollitt, Beata Grygielska, Bertrand.
IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation by Melanie Antl, Marie-Luise von Brühl, Christina Eiglsperger,
Rapid ubiquitination of Syk following GPVI activation in platelets
Volume 102, Issue 10, Pages (May 2012)
RGS10 shapes the hemostatic response to injury through its differential effects on intracellular signaling by platelet agonists by Peisong Ma, Shuchi Gupta,
Volume 124, Issue 5, Pages (May 2003)
Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice by Kellie R. Machlus, Jessica C. Cardenas, Frank C.
Histamine Contributes to Tissue Remodeling via Periostin Expression
Enhancing functional platelet release in vivo from in vitro–grown megakaryocytes using small molecule inhibitors by Danuta Jarocha, Karen K. Vo, Randolph.
Inter-α inhibitor proteins maintain neutrophils in a resting state by regulating shape and reducing ROS production by Soe Soe Htwe, Hidenori Wake, Keyue.
A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant by Shauna L. French, Claudia Thalmann, Paul F.
Volume 20, Issue 4, Pages (July 2017)
by Silvia Mele, Stephen Devereux, Andrea G
Rap1 binding to the talin 1 F0 domain makes a minimal contribution to murine platelet GPIIb-IIIa activation by Frederic Lagarrigue, Alexandre R. Gingras,
Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects by Constance C. F. M. J. Baaten, Frauke Swieringa, Tomasz Misztal,
Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors by Manu T. Kalathottukaren, A.
by Changjie Zhang, Anju Kelkar, and Sriram Neelamegham
Platelet MEKK3 regulates arterial thrombosis and myocardial infarct expansion in mice by Xuemei Fan, Conghui Wang, Panlai Shi, Wen Gao, Jianmin Gu, Yan.
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib by Alexander P. Bye, Amanda J. Unsworth,
The endogenous antimicrobial cathelicidin LL37 induces platelet activation and augments thrombus formation by Maryam F. Salamah, Divyashree Ravishankar,
ELMO1 deficiency enhances platelet function
by Defne Bayik, Debra Tross, Lydia A
Deletion of the Arp2/3 complex in megakaryocytes leads to microthrombocytopenia in mice by David S. Paul, Caterina Casari, Congying Wu, Raymond Piatt,
by Caroline Kardeby, Knut Fälker, Elizabeth J
Calpain cleaves phospholipid flippase ATP8A1 during apoptosis in platelets by Weidong Jing, Mehmet Yabas, Angelika Bröer, Lucy Coupland, Elizabeth E. Gardiner,
TREM-like transcript 1: a more sensitive marker of platelet activation than P-selectin in humans and mice by Christopher W. Smith, Zaher Raslan, Lola Parfitt,
by Kelly E. Johnson, Julia R. Ceglowski, Harvey G. Roweth, Jodi A
Platelet ATP secretion in response to agonist stimulation.
Aggregation tracings of platelets lacking PLCβ2/β3.
Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.
Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura by Liang Zheng, Yingying.
by Alyssa J. Moroi, Nicole M. Zwifelhofer, Matthew J. Riese, Debra K
ChREBPα enhances mitochondrial oxidative metabolism.
Src kinases mediate TSP-1 inhibition of AC and PKA activity.
by Fabian C. Verbij, Nicoletta Sorvillo, Paul H. P
Presentation transcript:

Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis by Manasa K. Nayak, Nirav Dhanesha, Prakash Doddapattar, Omar Rodriguez, Vijay K. Sonkar, Sanjana Dayal, and Anil K. Chauhan BloodAdv Volume 2(15):2029-2038 August 14, 2018 © 2018 by The American Society of Hematology

Manasa K. Nayak et al. Blood Adv 2018;2:2029-2038 © 2018 by The American Society of Hematology

DCA inhibits agonist-induced platelet aggregation. DCA inhibits agonist-induced platelet aggregation. PRP or washed platelets from human (A) and mouse (B) were stimulated with suboptimal doses of convulxin, collagen, ADP, and thrombin. Results are expressed as the percentage change in light transmission concerning the blank (platelet-poor plasma/buffer without platelets), set at 100%. The upper panel in each bar graph denotes the representative aggregation curves (blue, control; black, 10 mM DCA; red, 25 mM DCA). For mouse studies, PRP or washed platelets were pooled from 3 to 4 mice (n = 5 individual experiments per group). For human studies, PRP or washed platelets are from the individual donors (n = 5 per group). Values are mean ± SEM. *P < .05 vs control (vehicle). Manasa K. Nayak et al. Blood Adv 2018;2:2029-2038 © 2018 by The American Society of Hematology

DCA inhibits glucose uptake in agonist-induced platelet activation. DCA inhibits glucose uptake in agonist-induced platelet activation. Measurement of 2-DG uptake in washed human (A) and mouse (B) platelets with a luminescence-based assay kit. Luminescence (produced by 2DG6P) was monitored in resting and platelets response to suboptimal dose of collagen, convulxin, thrombin, and ADP. For mouse studies, washed platelets were pooled from 3 to 4 mice (n = 5 individual experiments per group). For human studies, washed platelets are from the individual donors (n = 5 per group). Values are mean ± SEM. *P < .05 vs unstimulated platelets; #P < .05 vs control (vehicle). Manasa K. Nayak et al. Blood Adv 2018;2:2029-2038 © 2018 by The American Society of Hematology

DCA inhibits aerobic glycolysis in convulxin-stimulated platelets. DCA inhibits aerobic glycolysis in convulxin-stimulated platelets. Pooled washed platelets from 5 mice were used to measure bioenergetics. OCR (A) and ECAR (B) were measured in platelets response to convulxin in the presence or absence of DCA (10 and 25 mM) with sequential injections of 1 μg/mL oligomycin, 1 μM proton ionophore FCCP, and 1 μM rotenone/0.5 μM myxothiazol. Convulxin was added at time 0 just before the microplates were put in the Seahorse extracellular flux analyzer. RP with or without DCA was used as a control. All the bioenergetic measurements were normalized to protein content per well. Values shown in bar graph are mean ± SEM, with n = 9 values per group. *P < .05 vs unstimulated platelets (no convulxin, blue bar); #P < .05 vs convulxin-stimulated platelets (violet bar). Convx, convulxin; Rot/Myx, rotenone/myxothiazol. Manasa K. Nayak et al. Blood Adv 2018;2:2029-2038 © 2018 by The American Society of Hematology

DCA inhibits TXB2 A2 production and ATP secretion in platelet response to collagen. DCA inhibits TXB2 A2 production and ATP secretion in platelet response to collagen. The level of TXB2 A2 generation was measured in human (A, left) and mouse (B, left) RP and in platelet response to suboptimal dose of collagen (0.46 μg). PRP samples were preincubated in the presence or absence of DCA (10 and 25 mM), aspirin (100 μM), and indomethacin (20 μM). The aggregation was performed for 3 minutes, and the reaction was stopped by quickly freezing the sample in a dry ice–methanol bath. Samples were prepared, and the level of TXA2 was measured with an enzyme-linked immunosorbent assay kit. ATP secretion was measured by luciferase/luciferin-based reaction. Luminescence generated by secreted ATP from human (A, right) and mouse (B, right) platelets were monitored using a Lumi-aggregometer. Asp., aspirin; Ind., indomethacine; NS, nonsignificant. Manasa K. Nayak et al. Blood Adv 2018;2:2029-2038 © 2018 by The American Society of Hematology

DCA inhibits phosphorylation of Syk and PLCγ2 in convulxin-stimulated platelets. DCA inhibits phosphorylation of Syk and PLCγ2 in convulxin-stimulated platelets. Washed platelets (0.2 × 109/mL) from human (A) and mouse (B) were preincubated with DCA (10 and 25 mM) for 10 minutes at room temperature and stimulated with convulxin (25 ng/mL) for 10 minutes. The upper panels in A and B show representative images of immunoblots of phospho-Syk (Tyr 525/526), total Syk, phospho-PLCγ2 (Tyr1217), and total PLCγ2. Bottom panels indicate densitometry analysis of immunoblots using ImageJ software. The data are expressed as a ratio of phospho-Syk/total Syk and phospho-PLCγ2/total PLCγ2. Values are mean ± SEM, with n = 5 human or mice per group. Manasa K. Nayak et al. Blood Adv 2018;2:2029-2038 © 2018 by The American Society of Hematology

DCA inhibits platelet aggregates/thrombus formation in vitro. DCA inhibits platelet aggregates/thrombus formation in vitro. The analysis was done using flow chamber system from Bioflux Microfluidics. Human (A) and mouse (B) whole blood pretreated with 50 mM DCA (lower channels) or control (upper channels) was perfused over a collagen-coated (150 μg/mL) surface for 10 minutes at a shear rate of 1500 s−1. Left panels show representative images taken using a 10× objective. Right panels show quantification of the surfaced area covered by fluorescent platelets after 10 minutes of perfusion. Four areas from different areas of flow chamber were analyzed from each blood sample. Data represent the mean percentage of surface area covered by fluorescence platelets ± SEM, with n = 5 per group for mice and 3 per group for the human. Manasa K. Nayak et al. Blood Adv 2018;2:2029-2038 © 2018 by The American Society of Hematology

DCA inhibits experimental arterial thrombosis without altering tail bleeding time. DCA inhibits experimental arterial thrombosis without altering tail bleeding time. (A) The tail-transection bleeding time was determined as the time taken for the initial cessation of bleeding after transection in vehicle or DCA-treated group. Each symbol represents a single mouse. Horizontal bar shows the mean of each group ± SEM, n = 15 per group. (B) Aggregation induced by collagen (0.5 µg/mL) in PRP from mice treated with DCA or vehicle. Upper panel denotes the representative aggregation curves (blue, vehicle; black, DCA). Values are represented as mean ± SEM, with n = 4 mice per group. (C) The left panel shows representative microphotographs (4× objective), and right panel shows time to occlusive thrombus in the FeCl3-induced carotid artery injury model. Each symbol represents a single mouse. Horizontal bars show the mean of each group ± SEM, with n = 8 to 10 per group. (D) The left panel shows representative microphotographs (10× objective), and right panel shows time mean fluorescence intensity in the laser-induced mesentery artery injury model. N = 10 to 12 vessels from 4 mice per group. *P < .05 compared with vehicle control. Platelets were labeled with calcein green. White line delineates vessel. Manasa K. Nayak et al. Blood Adv 2018;2:2029-2038 © 2018 by The American Society of Hematology